Pharmadrug Inc. (CSE: PHRX)
Canada
· Delayed Price · Currency is CAD 0.0150
+0.0050 (50.00%)
Nov 29, 2024, 10:29 AM EST
Pharmadrug Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | - | - | - | 0.01 | 0.68 | 0.61 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -98.97% | 11.97% | - | Upgrade
|
| Cost of Revenue | - | - | 0 | 0.01 | 0.5 | 0.36 | Upgrade
|
| Gross Profit | - | - | -0 | -0 | 0.18 | 0.25 | Upgrade
|
| Selling, General & Admin | 0.72 | 0.78 | 1.27 | 1.55 | 2.06 | 2.82 | Upgrade
|
| Research & Development | 0.1 | 0.23 | 0.71 | 0.55 | - | - | Upgrade
|
| Operating Expenses | 1.26 | 1.36 | 2.35 | 2.72 | 4.13 | 5.29 | Upgrade
|
| Operating Income | -1.26 | -1.36 | -2.36 | -2.72 | -3.95 | -5.04 | Upgrade
|
| Interest Expense | -0.46 | -0.33 | -0.22 | -0.06 | -0.35 | -0.48 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.03 | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0.73 | 0.07 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.04 | -0.06 | -0.05 | -0.06 | -4.41 | -0.22 | Upgrade
|
| EBT Excluding Unusual Items | -1.75 | -1.76 | -2.62 | -3.57 | -8.6 | -5.84 | Upgrade
|
| Merger & Restructuring Charges | -1.43 | -1.43 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.03 | -0.05 | -0.61 | -0.72 | 2.53 | -1.14 | Upgrade
|
| Asset Writedown | -10.14 | -10.14 | - | - | - | - | Upgrade
|
| Legal Settlements | 0.07 | 0.07 | -0.07 | - | - | - | Upgrade
|
| Other Unusual Items | -0.96 | -0.96 | 0.05 | - | 0.17 | - | Upgrade
|
| Pretax Income | -14.24 | -14.27 | -3.25 | -4.28 | -5.9 | -6.98 | Upgrade
|
| Income Tax Expense | -1.01 | -1.01 | -0.19 | - | -0.48 | -0.44 | Upgrade
|
| Earnings From Continuing Operations | -13.23 | -13.26 | -3.06 | -4.28 | -5.43 | -6.54 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -5.81 | -1.59 | - | - | Upgrade
|
| Net Income to Company | -13.23 | -13.26 | -8.88 | -5.87 | -5.43 | -6.54 | Upgrade
|
| Minority Interest in Earnings | 0.06 | 0.06 | - | 0.25 | 0.28 | 0.25 | Upgrade
|
| Net Income | -13.17 | -13.2 | -8.88 | -5.63 | -5.15 | -6.29 | Upgrade
|
| Net Income to Common | -13.17 | -13.2 | -8.88 | -5.63 | -5.15 | -6.29 | Upgrade
|
| Shares Outstanding (Basic) | 96 | 56 | 50 | 47 | 20 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 56 | 50 | 47 | 20 | 10 | Upgrade
|
| Shares Change (YoY) | 89.92% | 12.76% | 5.88% | 132.48% | 103.18% | 409.99% | Upgrade
|
| EPS (Basic) | -0.14 | -0.23 | -0.18 | -0.12 | -0.25 | -0.63 | Upgrade
|
| EPS (Diluted) | -0.14 | -0.23 | -0.18 | -0.12 | -0.25 | -0.63 | Upgrade
|
| Free Cash Flow | -1.05 | -0.67 | -2.26 | -4.13 | -1.82 | -2.35 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.05 | -0.09 | -0.09 | -0.23 | Upgrade
|
| Gross Margin | - | - | - | -30.75% | 26.63% | 41.48% | Upgrade
|
| Operating Margin | - | - | - | -38806.68% | -578.02% | -825.60% | Upgrade
|
| Profit Margin | - | - | - | -80275.25% | -753.33% | -1030.15% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -58906.35% | -266.35% | -384.84% | Upgrade
|
| EBITDA | -1.2 | -1.34 | -2.34 | -2.72 | -2.7 | -4.29 | Upgrade
|
| D&A For EBITDA | 0.05 | 0.03 | 0.01 | 0 | 1.26 | 0.75 | Upgrade
|
| EBIT | -1.26 | -1.36 | -2.36 | -2.72 | -3.95 | -5.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.